Healey ALS MyMatch Gemeinsames Screening-Protokoll (MCSP)
Healey ALS MyMatch Gemeinsames Screening-Protokoll (MCSP) zur Bestimmung der vorläufigen Eignung für ALS MyMatch Frühphasen-Studien
The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.
People who complete an MCSP Screening Visit will undergo:
- clinical assessments
- laboratory testing
- biomarker analyses
The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
The MyMatch Common Screening Protocol (MCSP) is an observational study that is part of the Healey ALS MyMatch program. Healey ALS MyMatch is an early phase (Phase 1b or 2a), Amyotrophic Lateral Sclerosis (ALS) clinical trial program. ALS MyMatch is designed to help match adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.
The first step in participating in Healey ALS MyMatch is to complete a screening visit for the MCSP. MCSP screening visit activities can be completed over a period of 45-days and some screening visit activities can be completed remotely. MCSP screening visit activities include:
- obtaining informed consent
- reviewing medical history
- collecting blood samples
- completing a 12-lead ECG
- completing questionnaires
To be eligible to participate in the MCSP, the following key criteria will need to be met: ALS diagnosis, SVC breathing score of equal to or greater than 65%, and ALS genetic testing.
The information collected at the MCSP screening visit helps researchers determine whether a participant might qualify for one or more treatment studies that are currently enrolling in the ALS MyMatch program. If a participant appears eligible for more than one study, then the participant may choose to consult with their doctor and decide which study would be a better fit for them.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Healey ALS MyMatch Clinical Operations Team
- Telefonnummer: 857-282-9210
- E-Mail: mghalsmymatch@mgb.org
Studienorte
-
-
Florida
-
Davie, Florida, Vereinigte Staaten, 33314
- Noch keine Rekrutierung
- Nova Southeastern University
-
Kontakt:
- Donovan Mott
- Telefonnummer: 954-203-2829
- E-Mail: Donovan.mott@nova.edu
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Noch keine Rekrutierung
- Northwestern University
-
Kontakt:
- Candace James
- Telefonnummer: 312-503-0747
- E-Mail: candace.james@northwestern.edu
-
Kontakt:
- ALS Research
- E-Mail: alsresearch@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital
-
Kontakt:
- Hattie Grant
- Telefonnummer: 617-643-7912
- E-Mail: healeysitemymatchmgh@mgb.org
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55414
- Noch keine Rekrutierung
- University of Minnesota
-
Kontakt:
- Tori Schirrick
- Telefonnummer: (612) 626-7300
- E-Mail: kaste125@umn.edu
-
Kontakt:
- Julia Munoz
- Telefonnummer: (612)-624-9987
- E-Mail: munoz156@umn.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The target populations for MCSP and ALS MyMatch trials will initially focus on subgroups of individuals with ALS, including those with early-stage disease. Some ALS MyMatch trials will further target those with specific biomarkers or genetic markers for inclusion in a specific trial.
Beschreibung
Inclusion Criteria:
- Ability to provide written informed consent.
- Adults > 18 years of age.
- Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.
- Available or pending clinically obtained CLIA ALS genetic panel report.
- Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.
- Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.
- Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to Hemoglobin ≥ 9 g/dL.
- Ability and willingness to complete all study procedures per SI's assessment.
- Negative pregnancy test at screening for women of child-bearing potential (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).
Exclusion Criteria:
-
Clinically significant unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.
-
Presence of cognitive or mental health disorders impairing ability to provide informed consent for the study per SI assessment.
-
Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)
-
Prior solid organ transplantation.
-
Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)
-
Screening 12-lead ECG showing QT interval corrected for rate (QTcF) > 470 msec for women and > 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.
-
Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:
- Serum alanine aminotransferase or aspartate aminotransferase > 3 times the upper limit of normal, or serum bilirubin > 1.5 × upper limit of normal
- Estimated GFR (eGFR) of < 30 mL/min/1.73m2
-
Other clinically significant electrolyte and metabolic abnormalities
-
If female, breastfeeding, pregnant, or of child-bearing potential and unwilling to use effective contraception for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.
-
Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.
-
Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
-
Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Preliminary eligibility to be matched to a MyMatch Trial
Zeitfenster: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.
|
To determine preliminary eligibility of early ALS (< 24 months from weakness onset) participants for actively enrolling ALS MyMatch trial(s) |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Repository for future research
Zeitfenster: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To build an ALS biofluid, genetic and data repository for future clinical and translational research. |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
|
Prevalence of gene mutations
Zeitfenster: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To characterize the prevalence of participants with causative or risk modifier gene mutations in the MCSP |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
|
Collect and bank samples
Zeitfenster: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To collect and bank blood samples for future biofluid biomarker analyses |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Neuromuskuläre Erkrankungen
- Stoffwechselerkrankungen
- Neurodegenerative Krankheiten
- Erkrankungen des Rückenmarks
- TDP-43 Proteinopathien
- Proteostase-Mängel
- Motoneuron-Krankheit
- Ernährungs- und Stoffwechselerkrankungen
- Amyotrophe Lateralsklerose
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2025P002080
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .